Last 12 months
Inside the activity.
1 purchase rows · 32 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 8 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 14 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 03, 2019 Filed Jul 4, 2019 00:11 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000145 · wf-form4_156219910020685.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,409 Underlying: Common Stock · 50,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 300,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| July 03, 2019 Filed Jul 4, 2019 00:11 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 34,721 | $21.03 | $730,182.63 |
DisclosureSEC source: 0000939767-19-000145 · wf-form4_156219910020685.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,870 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2019. F3 · kind: The shares were sold to cover the exercise price, tax withholding obligations, broker commissions and fees for the exercised stock options. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.92 to $21.24. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| July 03, 2019 Filed Jul 4, 2019 00:11 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 50,000 | $7.18 | $359,000.00 |
DisclosureSEC source: 0000939767-19-000145 · wf-form4_156219910020685.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| July 01, 2019 Filed Jul 4, 2019 00:13 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 40,000 | $21.58 | $863,200.00 |
DisclosureSEC source: 0000939767-19-000146 · wf-form4_156219917418366.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,168,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.40 to $21.79. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionOption (right to buy) · Derivative | 17,404 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · derivative · entry 14 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,404 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: On September 18, 2013, the Reporting Person was granted a performance-based stock option to purchase 84,000 shares of common stock under the Exelixis, Inc. 2011 Equity Incentive Plan. Vesting of the option is tied to performance goals set by the Compensation Committee ("Committee") as follows: (i) 50% of the option will vest if the Committee determines that top-line efficacy data received from the METEOR Phase 3 clinical trial of cabozantinib in metastatic renal cell carcinoma met its primary endpoint at a specified level, which the Committee determined had been achieved on July 20, 2015, resulting in the vesting of 50% of the option; and (ii) 50% of the option will vest if the Committee confirms the approval of cabozantinib by the U.S. Food and Drug Administration or European Medicines Agency for the treatment of metastatic castration-resistant prostate cancer, which the Committee determined could not be achieved on December 10, 2014, resulting in the forfeiture of 50% of the option. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionCommon Stock | 17,404 | $5.51 | $95,896.04 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · nonDerivative · entry 7 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionOption (right to buy) · Derivative | 24,596 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · derivative · entry 13 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,404 Underlying: Common Stock · 24,596 shares Expires 2020-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: On September 18, 2013, the Reporting Person was granted a performance-based stock option to purchase 84,000 shares of common stock under the Exelixis, Inc. 2011 Equity Incentive Plan. Vesting of the option is tied to performance goals set by the Compensation Committee ("Committee") as follows: (i) 50% of the option will vest if the Committee determines that top-line efficacy data received from the METEOR Phase 3 clinical trial of cabozantinib in metastatic renal cell carcinoma met its primary endpoint at a specified level, which the Committee determined had been achieved on July 20, 2015, resulting in the vesting of 50% of the option; and (ii) 50% of the option will vest if the Committee confirms the approval of cabozantinib by the U.S. Food and Drug Administration or European Medicines Agency for the treatment of metastatic castration-resistant prostate cancer, which the Committee determined could not be achieved on December 10, 2014, resulting in the forfeiture of 50% of the option. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionOption (right to buy) · Derivative | 75,404 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · derivative · entry 12 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 75,404 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
SaleCommon Stock | 100,000 | $20.67 | $2,067,000.00 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · nonDerivative · entry 6 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,197 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.42 to $20.87. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionCommon Stock | 24,596 | $5.51 | $135,523.96 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · nonDerivative · entry 5 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionCommon Stock | 75,404 | $1.70 | $128,186.80 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · nonDerivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionOption (right to buy) · Derivative | 4,596 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · derivative · entry 11 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,404 Underlying: Common Stock · 4,596 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option, representing the right to purchase a total of 400,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionOption (right to buy) · Derivative | 95,404 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · derivative · entry 10 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,404 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 123,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
SaleCommon Stock | 17,404 | $20.76 | $361,307.04 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · nonDerivative · entry 8 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,197 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.59 to $20.91. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 5 to this Form 4. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
SaleCommon Stock | 100,000 | $20.49 | $2,049,000.00 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · nonDerivative · entry 3 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,197 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.29 to $20.69. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionCommon Stock | 4,596 | $1.70 | $7,813.20 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2019 Filed Jun 20, 2019 01:30 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionCommon Stock | 95,404 | $5.56 | $530,446.24 |
DisclosureSEC source: 0000939767-19-000141 · wf-form4_156099419666093.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 49,374 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 13, 2019 Filed Jun 15, 2019 00:11 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionOption (right to buy) · Derivative | 27,596 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000140 · wf-form4_156055744704575.xml · derivative · entry 4 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,404 Underlying: Common Stock · 27,596 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 123,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| June 13, 2019 Filed Jun 15, 2019 00:11 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
SaleCommon Stock | 27,596 | $20.03 | $552,747.88 |
DisclosureSEC source: 0000939767-19-000140 · wf-form4_156055744704575.xml · nonDerivative · entry 2 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,197 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2019. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| June 13, 2019 Filed Jun 15, 2019 00:11 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
Exercise / conversionCommon Stock | 27,596 | $5.56 | $153,433.76 |
DisclosureSEC source: 0000939767-19-000140 · wf-form4_156055744704575.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 49,374 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 10, 2019 Filed Jun 13, 2019 00:16 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 1,000 | $20.23 | $20,230.00 |
DisclosureSEC source: 0000939767-19-000139 · wf-form4_156038495274650.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,453 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2018. F2 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 00:21 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 15,000 | $20.00 | $300,000.00 |
DisclosureSEC source: 0000939767-19-000138 · wf-form4_155978050296245.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| June 03, 2019 Filed Jun 6, 2019 00:21 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 25,000 | $19.61 | $490,250.00 |
DisclosureSEC source: 0000939767-19-000138 · wf-form4_155978050296245.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.45 to $19.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| May 29, 2019 Filed May 31, 2019 00:53 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 14,591 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0000939767-19-000137 · wf-form4_155926401044302.xml · derivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,409 Underlying: Common Stock · 14,591 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 300,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013. Read SEC document |
| May 29, 2019 Filed May 31, 2019 00:53 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 14,591 | $7.18 | $104,763.38 |
DisclosureSEC source: 0000939767-19-000137 · wf-form4_155926401044302.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:38 UTC |
SCANGOS GEORGE ADirector
|
GrantOption (right to buy) · Derivative | 42,641 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000132 · wf-form4_155874467224174.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:47 UTC |
Smith JulieDirector
|
GrantOption (right to buy) · Derivative | 42,641 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000136 · wf-form4_155874524378443.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:45 UTC |
Garber Alan MDirector
|
GrantOption (right to buy) · Derivative | 42,641 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000135 · wf-form4_155874509766298.xml · derivative · entry 1 Garber Alan M · CIK 0001312907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:43 UTC |
PAPADOPOULOS STELIOSDirector
|
GrantOption (right to buy) · Derivative | 20,634 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000134 · wf-form4_155874500148985.xml · derivative · entry 2 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2026-05-22 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:43 UTC |
PAPADOPOULOS STELIOSDirector
|
GrantCommon Stock | 10,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000134 · wf-form4_155874500148985.xml · nonDerivative · entry 1 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,568 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 23, 2020, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:40 UTC |
WYSZOMIERSKI JACK LDirector
|
GrantOption (right to buy) · Derivative | 20,634 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000133 · wf-form4_155874478556734.xml · derivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2026-05-22 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:40 UTC |
WYSZOMIERSKI JACK LDirector
|
GrantCommon Stock | 10,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000133 · wf-form4_155874478556734.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,526 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 23, 2020, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:35 UTC |
MARCHESI VINCENT TDirector
|
GrantOption (right to buy) · Derivative | 20,634 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000131 · wf-form4_155874452985856.xml · derivative · entry 2 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2026-05-22 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:35 UTC |
MARCHESI VINCENT TDirector
|
GrantCommon Stock | 10,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000131 · wf-form4_155874452985856.xml · nonDerivative · entry 1 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,167 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 23, 2020, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:32 UTC |
COHEN CHARLESDirector
|
GrantOption (right to buy) · Derivative | 42,641 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000130 · wf-form4_155874434720088.xml · derivative · entry 1 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:29 UTC |
WILLSEY LANCEDirector
|
GrantOption (right to buy) · Derivative | 42,641 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000128 · wf-form4_155874413638293.xml · derivative · entry 1 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:30 UTC |
FELDBAUM CARL BDirector
|
GrantOption (right to buy) · Derivative | 42,641 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000129 · wf-form4_155874423703690.xml · derivative · entry 1 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:27 UTC |
POSTE GEORGEDirector
|
GrantOption (right to buy) · Derivative | 20,634 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000127 · wf-form4_155874402459385.xml · derivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2026-05-22 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:27 UTC |
POSTE GEORGEDirector
|
GrantCommon Stock | 10,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000127 · wf-form4_155874402459385.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,792 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 23, 2020, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:24 UTC |
Freire Maria CDirector
|
GrantOption (right to buy) · Derivative | 20,634 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000126 · wf-form4_155874387896369.xml · derivative · entry 2 Freire Maria C · CIK 0001547999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2026-05-22 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:24 UTC |
Freire Maria CDirector
|
GrantCommon Stock | 10,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000126 · wf-form4_155874387896369.xml · nonDerivative · entry 1 Freire Maria C · CIK 0001547999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,374 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 23, 2020, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 20,907 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 21, 2019 Filed May 23, 2019 00:52 UTC |
SCANGOS GEORGE ADirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000121 · wf-form4_155857275798722.xml · derivative · entry 5 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| May 21, 2019 Filed May 23, 2019 00:52 UTC |
SCANGOS GEORGE ADirector
|
Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000121 · wf-form4_155857275798722.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,248,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2019 Filed May 11, 2019 00:35 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 1,000 | $19.58 | $19,580.00 |
DisclosureSEC source: 0000939767-19-000120 · wf-form4_155753488877907.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,453 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2018. F2 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,673 shares of common stock acquired on April 30, 2019, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:21 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 42,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000119 · wf-form4_155753408424671.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:21 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 42,000 | $20.15 | $846,300.00 |
DisclosureSEC source: 0000939767-19-000119 · wf-form4_155753408424671.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.27. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:21 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 42,000 | $5.56 | $233,520.00 |
DisclosureSEC source: 0000939767-19-000119 · wf-form4_155753408424671.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:20 UTC |
WILLSEY LANCEDirector
|
SaleCommon Stock | 50,000 | $20.36 | $1,018,000.00 |
DisclosureSEC source: 0000939767-19-000118 · wf-form4_155753399415415.xml · nonDerivative · entry 1 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,273 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.28 to $20.50. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| May 03, 2019 Filed May 4, 2019 00:55 UTC |
Senner Christopher J.EVP and CFO
|
SaleCommon Stock | 36,261 | $20.70 | $750,602.70 |
DisclosureSEC source: 0000939767-19-000113 · wf-form4_155693132529907.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,362 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.68 to $20.75. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 56,875 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 1,673 shares of common stock acquired on April 30, 2019, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. Read SEC document |
| May 02, 2019 Filed May 4, 2019 00:52 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 15,000 | $20.00 | $300,000.00 |
DisclosureSEC source: 0000939767-19-000111 · wf-form4_155693115338573.xml · nonDerivative · entry 2 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,233,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.02. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.